Damora Therapeutics shareholders elect directors, approve say-on-pay and E&Y ratification at 2026 annual meeting

Damora Therapeutics, Inc.

Elected Michael Landsittel and Cameron Turtle as Class III directors; ~51.4M votes for each, 29K withheld.
Advisory say-on-pay approved: 51,401,988 for, 3,546 against, 27,018 abstain.
Say-on-frequency: one-year option received 50,913,167 votes; Board adopts annual frequency.
Ratified Ernst & Young as auditor for FY2026: 54,977,317 for, 5,640 against, 26,981 abstain.
Quorum of 55,009,938 shares out of 60,303,212 outstanding was represented.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Damora Therapeutics, Inc. shareholders approved Election of Michael Landsittel and Cameron Turtle, D.Phil as Class III directors at the 2026-06-17 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-17

Exact text from the filing

1. Election of Directors Proposal . Nominees For Withheld Broker Non-Votes Michael Landsittel 51,403,541 29,011 3,577,386 Cameron Turtle, D.Phil 51,403,540 29,012 3,577,386

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Damora Therapeutics, Inc. shareholders approved Advisory vote to approve the compensation paid to the named executive officers at the 2026-06-17 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-17

Exact text from the filing

2. Say-on-Pay Proposal . For Against Abstain Broker Non-Votes 51,401,988 3,546 27,018 3,577,386

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Damora Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes to approve executive compensation at the 2026-06-17 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2026-06-17

Exact text from the filing

3. Say-on-Frequency Proposal . 1 Year 2 Years 3 Years Abstain 50,913,167 103 518,015 1,267

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Damora Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-17

Exact text from the filing

4. Ratification of Auditor Proposal . For Against Abstain Broker Non-Votes 54,977,317 5,640 26,981 -

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-274093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.